Clinical Trials Logo
  1. Home
  2. Neoplastic Syndrome
  3. NCT00489086

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Neoplastic Syndrome Clinical Trial

Official title:
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.

Clinical Trial Description

OBJECTIVES: - Determine whether topical tazarotene, administered over a period of 18 months as a chemopreventive agent, reduces the incidence of basal cell carcinomas (BCCs) on treated skin in patients with basal cell nevus syndrome (BCNS). - Expand and refine chemopreventive strategies in patients with BCNS who are at high risk for the development of BCCs. OUTLINE: This is an open-label, multicenter study. Patients apply topical tazarotene cream to the face once daily for 18 months in the absence of unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00489086
Study type Interventional
Source UCSF Benioff Children's Hospital Oakland
Contact
Status Completed
Phase Phase 2
Start date July 2004
Completion date June 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00454376 - Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Phase 4
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00427349 - AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Phase 2
Completed NCT00416767 - Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Phase 2
Completed NCT01553448 - Studying Gene Expression in Samples From Younger Patients With Neuroblastoma N/A
Completed NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3
Completed NCT00006368 - Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Phase 1
Completed NCT00433485 - Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants Phase 1